abrdn Private Equity Opportunities Trust <sup>plc</sup>



# Making private equity opportunities available to all


Analyst and Investor Presentation – January 2023

For professional investors only – not for public distribution

### abrdn Private Equity Opportunities Trust plc (the "Company" or "APEO") is □obrd∩ an investment trust with a premium listing on the London Stock Exchange

APEO provides investors with exposure to leading private equity funds and private companies, mainly in Europe. It invests through the primary and secondary funds markets, and co-investments.

Its investment objective is to achieve longterm total returns for investors and its policy is to maintain a broadly diversified portfolio by country, industry sector, maturity and number of underlying investments.



A diversified portfolio of private equity funds and co-investments principally focused on the European mid-market.


APEO partners with some of the leading private equity firms in Europe, through funds and co-investments. Our 12 core European private equity relationships represent around 59% of NAV.



Through funds and co-investments, these private equity firms then invest into market-leading private companies, some of which are household names, but many of which are not widely known.



This approach, developed over 22 years, has created a portfolio that provides underlying exposure to over 650 underlying private companies, well-balanced across sectors and vintages.



As at 30 September 2022. Based on the latest available information from underlying managers. Figures represent % of total value of underlying private compan **#%** exposure. This excludes any underlying funds and co-investments held through the Company portfolio.

© owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate abrdn's investment management style and not as an indication of performance.

# The Manager



# abrdn Private Equity

### abrdn

### Experienced team providing access to best performance areas of private equity



Source: abrdn, 30 June 2022. AUM is calculated as Net Asset Value + Unfunded

# **APEO team and senior investment resource**

APEO investment team and senior management team with an average industry experience of 22 years



#### Wider abrdn Private Equity team

- Multi-functional expertise including marketing, finance and investment trust specialists
- Global primary, secondaries and co-investment teams
- Provides broad market coverage and sourcing capability
- Supported by dedicated legal and back office teams

#### APEO governance

- Quarterly APEO board meetings
- European Investment Committee process
- APEO Portfolio Management Committee

Cabrdo

# **Investment Strategy**



# Access

Making private equity opportunities available to all types and sizes of investors


APEO gives investor access to high quality private equity managers and private companies




# Consistency

APEO has a history and track record of more than 20 years

A rigorous and disciplined approach to investment analysis that delivers consistent long-term NAV returns across market cycles





### abrdn

### Cabrdn

# Focus

The APEO portfolio is focused on one of the most established and consistently performing parts of the growing private markets universe

Building and managing a carefully selected and continually evolving portfolio of the best managers, funds and co-investments

### **59%**

Portfolio NAV allocated to 12 core European managers

PERMIRA VITRUVIAN INVESTIGUISTIA NORDIC CAPITAL TRITON

ArchiMed

nt International IK Partners

(capiton **XHC** ALTOR FUNDS European Private Equity Market Statistics


**\$848.5bn**<sup>1</sup> European Private Equity AUM<sup>2</sup>

**3,456**<sup>1</sup> European based Private Equity Firms<sup>3</sup>

**12** APEO Core Managers

 As at 30 June 2022. Source; Preqin
 European private equity AUM (NAV plus dry powder) (buyout, growth, turnaround)
 European based Private Equity Firms (buyouts, growth, turnaround)

#### APEO's Selective Approach In Large Private Markets Universe




# Focus

### abrdn

Access to a carefully selected portfolio of top-performing private equity managers, built from years of strong relationships and independent research

Advent International ALTOR **IK Partners** FUNDS PERMIRA **nvest**industria Triton capiton **XHO** ArchiMed VITRUVIAN ...and top 10 investments representing ~38% of portfolio NAV

59% portfolio NAV to 12 core European managers<sup>1</sup> ...




75%+ of our investments fall within top or second quartile<sup>2,3</sup>

Source: <sup>1</sup> abrdn, 30 September 2022. <sup>2</sup> From TVPI perspective; TVPI defined as Total value over paid in capital, representing the return multiple of capital invested, net of management fees and carried interest; <sup>3</sup> Source: Burgiss, data from 1999 – 2017 as at 30 June 2022. <sup>©</sup> owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance

Past performance does not predict future returns

# Focus

Backing leading private equity managers through targeted deployment




Source: abrdn. © owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate abrdns' investment management style and not as an indication of performance. Logo inside a dashed box represents a co-investment \*Company name cannot yet be disclosed due to confidentiality restrictions.

# Expertise

Our investment management team has specialist knowledge in European markets, with over two decades in the European mid-market


North America

23%



# **Expertise**

Mid-market buyout remains APEO's core focus, with the ability to invest selectively in adjacent areas



#### Source: abrdn © owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate abrdns' investment management style and not as an indication of performance. Logo inside a dashed box represents a co-investment \*Company name cannot yet be disclosed due to confidentiality restrictions.

Cobrdo

# Expertise


It's hard to really know what is happening inside a firm. In APEO we back managers with whom we have a long-term relationship, typically over a decade

Length of investing relationship with APEO manager

	PE Manager Year of first investment			Years abrdn Private Equity has invested in the manager																					
			≤'01	ʻ02	'03	'04	'05	5 '06	<b>'07</b>	<b>'</b> 0'	8 '0	09	'10	'11	'12	'13	'14	'15	'16	'17	'18	'19	'20	'21	ʻ22
Advent International	Advent International	2001																							
ALTOR FUNDS	Altor	2003																							
capiton	Capiton	2009																							
жНg	Нд	2001																							
<b>IK Partners</b>	IK	1997																							
Nordic Capital	Nordic Capital	2003																							
PAL	ΡΑΙ	2005																							
PERMIRA	Permira	2000																							
Triton	Triton	2009																							
	Vitruvian	2007																							

# Diversification

Portfolio well-balanced by country, with a bias to Northwest Europe




#### Source: abrdn, 30 September 2022.

Sector exposure



Diversification Portfolio of over 600 underlying private companies, well-balanced across sectors and vintages


#### Information Technology 4% 1% Healthcare 20% 11% Industrials Discretionary 12% ■ Consumer Staples Financials 20% Materials 14% Energy 18%



### abrdn

# **Responsible Investment**

ESG is integrated into the Manager's investment process



### abrdn

#### Source: abrdn, 30 September 2022

40%

30%

20%


10%

0%

85%

Sep-20

Primaries



80%

Sep-21

Secondaries

70%

Sep-22

# **Evolving portfolio**

abrdn

APEO introduced co-investments in 2019 and is deploying a larger share of APEO's capital via co-investments and secondaries, bringing numerous advantages

63%

Sep-25E

Co-investments

APEO's portfolio is evolving toward direct coinvestments

Co-investments, and secondaries, provide additional benefits to APEO, including:


- Greater control over capital deployment and cash management
- Targeting investments in sectors / sub-sectors
  which have particularly attractive characteristics
- Increasing exposure to specific deals
- Benefitting from lower costs
- J-curve mitigation

# Performance




# APEO highlights for the 12 months to 30 Sept 2022 abrdo

Resilient portfolio performance especially given greater uncertainty in the global economy



### APEO's historical NAV growth

Over a decade of year-on-year NAV growth; record performance in 2021 and resilient NAV growth over 2022



■ NAV + dividend change over time

#### Past performance does not predict future returns

## **Cashflow activity**

FY 2022 fund distributions remained ahead of fund drawdowns; portfolio exits realised at an average **20%** uplift<sup>1</sup> during FY22

GeneraLife £200.0m \* AutoForm £180.0m Forming Reality £160.0m - $|\infty$ £140.0m NordicTrustee BIDTECHNOLOGY £120.0m £100.0m CHRZSO £80.0m £60.0m Bruneau tricor £40.0m £20.0m veonet £0.0m Breathing-Speaking-Living Drawdowns Distributions  $\square Q1 \square Q2 \square Q3 \square Q4$ millerhomes

Portfolio fund cashflows FY 2022

Source: abrdn, 30 September 2022. <sup>1</sup> Calculated as gross multiple realised on exit compared to gross multiple 2 quarters prior. © owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance

### abrdn

Notable portfolio exits FY22

## Top 10 portfolio companies – 16.4% portfolio NAV

The largest underlying portfolio companies are all continuing to perform strongly in spite of a challenging market backdrop with co-investments increasingly dominating the top 10 portfolio companies

No.	Company	Sector	Fund	% of portfolio NAV
1	<b>MACTION M</b>	Consumer staples	Co-investment	5.0%
2	Oaccess	Technology	Hg Genesis 8	2.3%
3	АСТ	Industrials	Co-investment	1.5%
4	NAMSA	Healthcare	Co-investment	1.4%
5	<b>R1</b> °	Healthcare	Towerbrook Investors IV	1.1%
6	EUROPEAN CAMPING GROUP	Consumer staples	Co-investment	1.1%
7	FRONERI	Consumer staples	Co-investment	1.1%
8		Consumer Staples	Co-investment	1.0%
9	Undisclosed company	Healthcare	Co-investment	1.0%
10	Binding 🍄 Site 🖶	Healthcare	Nordic Capital VII	1.0%

Source: abrdn, 30 September 2022. (a) owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate abrdn's investment management style and not as an indication of performance.

abrdo

### Top 50 portfolio companies – key metrics



Median valuation of <u>14.3x</u> at 30 September 2022; resilient operational performance with <u>>20% LTM growth</u> at the topline and EBITDA levels

Top companies	% portfolio	Median valuation multiple	Median leverage multiple	LTM revenue growth	LTM EBITDA growth %
10	16.4%	17.3x	4.2x	28.4%	19.7%
30	31.8%	14.8x	4.0x	19.7%	20.9%
50	42.3%	14.3x	4.3x	22.7%	23.8%

# Co-investment portfolio (1/2)

### A young portfolio performing well so far; 58% valuation growth in FY 2022

Company	Investment Date	Geography	Sector	Description	% portfolio NAV	Performance to plan
Mademoiselle DESSERTS	Feb 19	France	Food	Dessert and confectionery producer	0.4%	On plan
///ACTION///	Jan 20	Netherlands	Consumer Staples	Non-food discount retailer	5.0%	Ahead of plan
💊 VISMA	Sep 20	Nordics	Software	Accounting software and services	0.7%	Ahead of plan
NAMSA°	Dec 20	US	Healthcare	Provider of medical devices	1.4%	Ahead of plan
FUNECAP	Feb 21	France	Services	Funeral services	0.5%	Ahead of plan
boost·ai	Mar 21	Nordics	Software	Conversational AI	0.3%	On plan
<b>KD Pharma Group</b> Creating Health Solutions	Jun 21	Germany	Healthcare	Manufacturer of Omega-3 acids	0.1%	On plan
Undisclosed company	Jul 21	Canada	Healthcare	Medical aesthetics company	1.0%	On plan
Wundesperter	Jul 21	Germany	Healthcare	Homecare for chronic wounds	0.5%	On plan
Questel	Jul 21	France / Global	Services	Intelligence Software	0.8%	On plan
'planet	Jul 21	Ireland / Global	Software	Payment services for retail/hospitality	0.7%	On plan

Source: abrdn, 30 September 2022. © owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance

# Co-investment portfolio (2/2)

### A young portfolio performing well so far; 58% valuation growth in FY 2022

Company	Investment Date	Geography	Sector	Description	% Total NAV	Performance to plan
<b>insight</b> software	Aug 21	US	Software	Financial reporting software	0.9%	On plan
riskalyze <sup>®</sup>	Sep 21	US	Software	Risk tolerance software	0.8%	On plan
	Oct 21	UK	Consumer discretionary	Ecommerce sports retailer	0.5%	On plan
SUANFARMA	Oct 21	Spain	Healthcare	Active pharmaceutical ingredients	0.5%	On plan
NUCLEM TOHNOLOGIES	Nov 21	US	Healthcare	Medical diagnostics	0.8%	On plan
Tropicana	Nov 21	US / UK	Food	Fruit juice and smoothies	0.8%	On plan
EUROPEAN CAMPING GROUP	Nov 21	France	Consumer discretionary	Outdoor accommodation holidays	1.1%	Ahead of Plan
NGE	Nov 21	France	Services	Infrastructure Services	0.7%	On plan
АСТ	Mar 22	Global	Services	Carbon offset solutions	1.5%	Ahead of Plan
	Mar 22	Spain	Consumer discretionary	Specialist grocery retailer	1.0%	On plan
<pre></pre>	May 22	UK / Global	Services	Insurance software and underwriting	0.6%	On plan

Source: abrdn, 30 September 2022. © owned by each of the corporate entities named in the respective logos. Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance

## Balance sheet and outstanding commitments




Strong balance sheet position provides downside protection

#### Cash and debt facility

- £20.3m cash as at 31 December 2022
- In October 2022 the debt facility was increased in size from £200m to £300m and the duration extended by a year to December 2025
- £237.5m of APEO's £300m debt facility remains undrawn as at 31 December 2022

#### **Outstanding commitments**

- Outstanding commitments of £709.7m at 31 Dec 2022 (including an estimated £81.3m unlikely to be drawn)
- Overcommitment ratio<sup>1</sup> of 39%, at the lower-mid end of our long-term target range (30-75%)



#### Current cash balance and debt facility as % portfolio NAV

Source: abrdn, 30 September 2022; 1. Outstanding commitments less cash and cash equivalents and the value of undrawn loan facilities divided by portfolio NAV.

# **Case studies**









# **Co-investment Case Study – ACT**



#### Transaction details

Transaction typeCo-investmentSponsorBridgepointInvestment€10.0mDeal sizeLargeInvestment year2021





#### Company overview

ACT is the largest specialist intermediary in the environmental certification market globally, offering 80 products across five core markets, with its headquarters in the Netherlands and hubs across Europe, the US and China.

ACT intermediates between sellers of certificates / offsets (e.g. renewable energy producers) and buyers (e.g. businesses with a need to prove compliance with a regulatory standard or offset emissions), leveraging its large network and technical and regulatory know-how to advise companies and trade certificates, often 'making a market' in new areas as a first mover.

Environmental certificates are an increasingly important instrument in successfully managing climate change and are becoming essential for organisations that are required to reduce greenhouse gases from operations.

#### The opportunity

After tracking the company for many years and getting to know the founders, Bridgepoint was successful in agreeing to acquire a large minority shareholding in ACT in Q4 2021 (APEO subsequently invested in early 2022).

Led by one of the original founders and his highly entrepreneurial management team, ACT is well positioned in a highly attractive market, benefitting from megatrend environmental tailwinds, that is forecast to grow at 15%+ per annum.

Supported by Bridgepoint, management is planning to develop further its core products (such as guarantee of origin certificates and biomethane) and take them into new geographies; grow recently established products (such as bio certificates) and capture more of the value chain

There is also potential to pursue targeted M&A.





# Primary Case Study – Investindustrial Growth III



#### **Transaction details**

<u>Transaction type</u> <u>Geographic focus</u>	Primary Western Europe with a focus on Southern Europe
<u>Vintage</u>	2022
APEO investment	€30.0m
<u>size</u> Fund size	€1.0bn



#### **Previous/current investments**







#### Manager overview

- Investindustrial is a leading private equity manager in Southern Europe with excellent networks and a high quality and well-resourced team
- The firm is focused on taking majority or control positions in mid-market companies, primarily across the Industrial, Healthcare & Services, Consumer and Technology sectors.
- Investindustrial has a strong Southern European heritage and specialism but today operates globally, with a team of c.160 professionals representing 21 nationalities, based across offices in Switzerland, Spain, United Kingdom, France, United States, Luxembourg, and China.
- The firm covers the entire mid-market across its mid-market and growth investment strategies. The growth strategy is differentiated by its focus on the attractive lower mid-market space and specialism in Southern Europe

#### **APEO's exposure**

- The Manager's relationship with Investindustrial goes back 15 years, with a first commitment to Investindustrial IV in 2008. abrdn has committed to every Investindustrial fund since that time
- APEO first invested with Investindustrial in 2018 through Growth Fund I and subsequently it committed to Investindustrial VII in 2019

Project Ivy -Secondary



# Secondary Case Study – Project Ivy

### abrdn

#### Transaction details

<u>Transaction type</u> <u>Geographic focus</u> Europe and North America

<u>Vintage years</u> 2011 - 2019

<u>APEO's secondary</u>€11.6m <u>exposure</u> <u>Company size</u> Mid-Market

#### **Transaction overview**

- The Seller was looking to manage its eclectic mix of private markets exposure and generate liquidity via a portfolio sale comprising numerous funds and strategies
- The Manger was able to carve out three specific buyout fund interests from the wider portfolio sale process

#### **Underlying investments**

- Portfolio of three funds with vintages ranging from 2011 to 2019, with the majority of value concentrated in the younger funds but with near-term cash flows expected from the older assets
- 27 high quality underlying portfolio companies, across a range of geographies and sectors

#### Why we invested

- Unusual deal dynamics rare opportunity to carve out interests in funds managed by three highly sought-after buyout managers from a larger portfolio sale at attractive relative pricing
- High conviction in the assets being acquired the Manager's existing knowledge of the underlying portfolios and confidence in the managers of the funds provided the conviction to pursue and secure this opportunity
- Strong portfolio fit and diversified profile all three funds are managed by core APEO managers and the underlying portfolios offer an attractive balance of short-term cash generation and longer-term value growth potential

#### Current investments

AMERICAN



ALTOR


# Summary



# Summary

abrdn

Diversified portfolio of leading private companies, by investing with or alongside high quality private equity managers, principally focused on European mid-market businesses



# Appendices



### Discrete performance

Total return (annualised)	1 year	3 years	5 years	10 years	Since Inception
APEO Share Price	-15.1%	9.1%	7.8%	13.2%	9.0%
APEO NAV	14.1%	21.0%	17.4%	15.6%	11.7%
FTSE All-Share Index	-4.0%	0.8%	2.2%	6.0%	5.0%

Annual total return	30 Jun 22	30 Jun 21	30 Jun 20	30 Jun 19	30 Jun 18
APEO Share Price	-15.1%	60.6%	-4.6%	5.7%	5.8%
APEO NAV	14.8%	38.1%	11.7%	10.6%	14.0%
FTSE All-Share Index	-4.0%	27.9%	-16.6%	2.7%	5.9%

**Investment objective:** To achieve long term total returns through holding a diversified portfolio of private equity funds and direct investments into private companies alongside private equity managers ("co-investments"), a majority of which will have a European focus.

Source: abrdn, 30 September 2022

### **APEO** portfolio

### abrdn

### Largest 10 private equity investments – 35.6% Total Fund NAV

24.862

35,000

84.1%

50

18,616

35,000

64.3%

101

1	#CTION //	Since its establishment in 1993, Benelux-based Action discount retailer in the region with more than 2,100 sto		
•	HL HUN	31 2020 Co-Investment 1 SCSp	30/09/22	30/09/21
5.1% Fund Size: £2.5bn Sector: Consumer staples Location: Netherlands Year of Investment: 2020 2021: 4.0%) Private Equity Manager: 3i Group plc	Fund Size: €2.5bn	Value (£'000)	58,695	41,454
	Cost (£'000)	22,630	22,630	
		Commitment (€'000)	26,540	26,540
		Amount Funded	100.0%	100.0%
	Investment: Co-investment Website: www.action.nl	Income (£'000)*	1,771	-
2		Invests in attractive niches within business & financial technology sectors	services, healthcare, indus	trial, retail and
•	Advent International	Advent International Global Private Equity VIII	30/09/22	30/09/21
4.5%	Fund Size: €13.0bn	Value (£'000)	52,171	55,818
of NAV		Cost (£'000)	31,652	31,102
OTNAV	Strategy: Mid to large buyouts Enterprise Value of Investments: \$200m-\$3bp	Commitment (€'000)	45,000	45,000

(30 September 2021: 5.4%) Geography: Global with a focus and North America Website: www.adventinternat

, <b>s:\$</b> 200m- <b>\$</b> 3bn	Commitment (€'000)	45,000	45,000
us on Europe	Amount Funded	100.0%	95.2%
tional.com	Income (£'000)*	-	-
	Undertakes medium and large sized buyout transactions acros geographies	s a range of Industr	1es and
	CVC Capital Partners VII	30/09/22	30/09/21
	Value (£'000)	44,399	28,902

3.8% Fund Size: €16.4bn of NAV Strategy: Mid to large buyouts Enter (30 September 2021: 2.8%) Geog Webs

	Investory and the strend become the			
site: <u>www.cvc.com</u>	Income (£'000)*			
graphy: Europe and North America	Amount Funded			
rprise Value of investments: €500m-€5bn	Commitment (€'000)			

4.	×Нд
3.6%	Fund Size: £2.5bn
5.070	Strategy: Mid-market buyou
of NAV	Enterprise Value of investmen

**Capital Partners** 

3.

(30 September 2021: 3.0%)

uts Enterprise Value of Investments: £100m-£500m Geography: Northern Europe Website: www.hgcapital.com

Invests in medium sized buyout transactions in the technology and services sectors, primarily in Northern Europe			
30/09/22	30/09/21		
42,144	30,769		
12,668	13,083		
22,000	22,000		
79.5%	67.1%		
-	-		
	30/09/22 42,144 12,668 22,000		

5.	Investment	Invests in growth strategies supporting business transformation. Unique Northern Continental European footprint		
•	Partners	IK Fund VIII	30/09/22	30/09/21
3.3%		Value (£'000)	38,225	35,006
of NAV	Fund Size: €1.9bn Strategy: Mid-market buyouts	Cost (£'000)	22,947	28,909
	Enterprise Value of Investments: €100m-€500m	Commitment (€'000)	46,000	46,000
		Amount Funded	94.7%	94.7%
	website: www.ikinvest.com	Income (£'000)*	4	391

Cost (£'000)

6.		Focuses on investing in and developing medium-sized companies with a Nordic origin that offer potential for value creation through revenue growth, margin expansion, improved capital management and strategic re-positioning			
~ ~~ ⁄	ALTOR FUNDS	Altor Fund IV	30/09/22	30/09/21	
3.2%	Fund Size: €2.1bn Strategy: Mid-market buyouts Enterprise Value of Investments: €50m-€500m Geography: Northern Europe Website: www.altor.com	Value (£'000)	37,158	51,229	
of NAV		Cost (£'000)	27,886	30,679	
(30 September 2021: 4.9%)		Commitment (€'000)	55,000	55,000	
		Amount Funded	73.2%	69.7%	
		Income (£'000)*	847	2,614	
7.		A diversified secondary transaction comprising large	diversified secondary transaction comprising large cap buyout funds in Europe and the		
<b>U</b>		Structured Solutions IV Primary Holdings	30/09/22	30/09/2	
2 20/	Fund Size: \$125m	Value (£'000)	36,504	28,507	
3.2%	Strategy: Various	Cost (£'000)	27,594	28,093	
of NAV	Enterprise Value of investments: \$500m-\$5bn	Commitment (\$'000)	62,500	62,500	
30 September 2021: 2.7%)	Geography: Europe and North America Website: <u>N/A</u>	Amount Funded	62.9%	61.59	
2021:2.7%)					
		Income (£'000)*	-	Roated south	
8.	Nonpole Campan	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob	albasis		
-	NORDIC CAPITAL	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX	al basis 30/09/22	30/09/2	
8. 3.1%		Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000)	30/09/22 35,841	<b>30/09/2</b> 43,119	
-		Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX $Value (\pounds'000)$ $Cost (\pounds'000)$	30/09/22 35,841 22,355	<b>30/09/2</b> 43,119 21,065	
<b>3.1%</b> of NAV	Fund Size: €4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: €200m-800m	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000)	30/09/22 35,841	<b>30/09/2</b> 43,119 21,065	
3.1%	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: £200m-800m Geography: Northern Europe (Global in	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX $Value (\pounds'000)$ $Cost (\pounds'000)$	30/09/22 35,841 22,355	alcated secto 30/09/2 43,119 21,065 30,000 79.39	
<b>3.1%</b> of NAV	Fund Size: €4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: €200m-800m	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000)	ad basis 30/09/22 35,841 22,355 30,000	<b>30/09/2</b> 43,11 21,06 30,000	
<b>3.1%</b> of NAV	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: £200m-800m Geography: Northern Europe (Global in Healthcare) Website: www.nordiccapital.com	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (£'000) Amount Funded	ad basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints	30/09/2 43,119 21,065 30,000 79.3%	
3.1% of NAV 30 September 2021:4.2%)	Fund Size: €4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: €200m-800m Geography: Northern Europe (Global in Healthcare)	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on agio Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000) Amount Funded Income (£'000)	ad basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints	30/09/2 43,111 21,061 30,000 79,39 	
3.1% of NAV <sup>30 September</sup> <sup>3021:42%</sup>	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: £200m-800m Geography: Northern Europe (Global in Healthcare) Website: www.nordiccapital.com Exponent	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glot Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000) Amount Funded Income (£'000) Target businesses have strong market positions, evide capable of transformation. Companies often have a s	al basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints gnificant international footg	30/09/2 43,114 21,069 30,000 79,39 	
3.1% of NAV 30 September 2021:4.2%)	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: £200m-800m Geography: Northern Europe (Global in Healthcare) Website: www.nordiccapital.com Exponent Fund Size: £1.0bn	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000) Amount Funded Income (£'000) Target businesses have strong market positions, evid copable of transformation. Companies often have a si Exponent Private Equity Partners III, LP.	ad basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints ignificant international footp 30/09/22	30/09/2 43,11 21,06 30,00 79,39 79,39 30,00 79,39 30,00 2 30,00 2 37,70	
3.1% of NAV 30 September 2021:42%) 3.0% of NAV	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of Investments: £200m-800m Geography: Northern Europe (Global in Healthcare) Website: www.nordiccapital.com Exponent	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000) Amount Funded Income (£'000) Target businesses have strong market positions, evid copable of transformation. Companies often have a si Exponent Private Equity Partners III, LP. Value (£'000)	ad basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints ignificant international footy 30/09/22 34,963	30/09/2 43,111 21,063 30,000 79,39 sound are 30/09/2 37,70 25,26	
3.1% of NAV <sup>30 September</sup> 2021:4.2%) 3.0%	Fund Size: £4.3bn Strategy: Mid to large buyouts Enterprise Value of investments: £200m-800m Geography: Northern Europe (Global in Healthcare) Website: www.nordiccapital.com Exponent Fund Size: £1.0bn Strategy: Mid-market buyouts	Invests in medium to large-sized buyout deals in North teams, with the ability to invest in healthcare on a glob Nordic Capital Fund IX Value (£'000) Cost (£'000) Commitment (€'000) Amount Funded Income (£'000) Target businesses have strong market positions, evid capable of transformation. Companies often have a si Exponent Private Equity Partners III, LP. Value (£'000) Cost (£'000)	al basis 30/09/22 35,841 22,355 30,000 89.0% - ence of historical constraints ignificant international footy 30/09/22 34,963 22,749	30/09/2 43,119 21,065 30,000 79.3%	

Contro

#### TOWERBROOK

2.8% Fund Size: \$3.6bn of NAV

10,

(30 September 2021: 3.5%)

Strategy: Mid-market buyouts Enterprise Value of Investments: \$200m-\$1bn Geography: Europe and North America Website: www.towerbrook.com

Control-oriented private equity investments in mid-market companies in Europe and North America, principally on a proprietary basis and in situations characterized by complexity					
TowerBrook Investors IV	30/09/22	30/09/21			
Value (£'000)	31,936	35,816			
Cost (£'000)	16,056	16,947			
Commitment (\$'000)	36,561	36,561			
Amount Funded	61.8%	59.9%			
Income (£'000)*	72	456			

### Key Risks

### abrdn

- The value of investments, and the income from them, can go down as well as up and investors may get back less than the amount invested.
- Past performance is not a guide to future results.
- Investment trusts are specialised investments and may not be appropriate for all investors.
- There is no guarantee that the market price of a Trust's shares will fully reflect its underlying Net Asset Value.
- As with all stock exchange investments the value of the Trust shares purchased will immediately fall by the difference between the buying and selling prices, the bid-offer spread. If trading volumes fall, the bid-offer spread can widen.
- Investment trusts can borrow money in order to enhance investment returns. This is known as 'gearing' or 'leverage'., However, the use of gearing can result in share prices being more volatile and subject to sudden or large falls in value. Where permitted an investment trust may invest in other investment trusts that utilise gearing which will exaggerate market movements, both up and down.
- The value of tax benefits depends on individual circumstances and the favourable tax treatment for ISAs may not be maintained. If
- you are a basic rate tax payer and you do not anticipate any liability to Capital Gains Tax, you should consider if the advantages of an ISA investment justify the additional management cost/charges incurred.
- Investing globally can bring additional returns and diversify risk. However, currency exchange rate fluctuations may have a positive or
- negative impact on the value of your investment.
- Certain funds can invest into other funds which themselves invest in assets such as bonds, company shares, cash and currencies.
- Where an Investment Trust is a fund of funds vehicle, it will have two layers of fees and expenses at the level of the Trust and also at the level of the underlying funds held by the Trust. This means that any returns generated for an investor will be after both layers of fees and expenses.
- Specialist funds which invest in small markets or sectors of industry are likely to be more volatile than more diversified trusts.
- The Company's investments may include unquoted and/or private equity investments which are not publicly traded or freely marketable and may therefore prove difficult to redeem. In addition, the potential volatility of investments in unquoted securities may increase the risk to the value of the investment.

### Important information

The MSCI information may only be used for your internal use, may not be reproduced or re-disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from marketing) any kind of investment decision and may not be relied on as such. Historical data and analysis, should not be taken as an indication or guarantee of any future performance analysis forecast or prediction. The MSCI information is provided on an 'as is' basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the 'MSCI' Parties) expressly disclaims all warranties (including without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

FTSE International Limited ('FTSE') © FTSE 2023. 'FTSE®' is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under licence. RAFI® is a registered trademark of Research Affiliates, LLC. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent

Other important information: An investment trust should be considered only as part of a balanced portfolio. The information contained in this document should not be considered as an offer, solicitation or investment recommendation to deal in the shares of any securities or financial instruments. It is not intended for distribution or use by any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication or use would be prohibited. Nothing herein constitutes investment, legal, tax or other advice and is not to be relied upon in making an investment or other decision. No recommendation is made, positive or otherwise, regarding individual securities mentioned. This is not an invitation to subscribe for shares and is by way of information only. Subscriptions will only be received and shares issued on the basis of the current Key Information Document (KID). These can be obtained free of charge from Aberdeen Asset Managers Limited, PO Box 11020, Chelmsford, Essex, CM99 2DB or available on www.invtrusts.co.uk. Any data contained herein which is attributed to a third party ("Third Party Data") is the property of (a) third party supplier(s) (the "Owner") and is licensed for use by abrdn\*. Third Party Data may not be copied or distributed. Third Party Data is provided "as is" and is not warranted to be accurate, complete or timely. To the extent permitted by applicable law, none of the Owner, abrdn\* or any other third party (including any third party involved in providing and/or compiling Third Party Data) is all have any liability for Third Party Data relates. \* abrdn means the relevant member of abrdn group, being abrdn PLC together with its subsidiaries, subsidiary undertakings and associated companies (whether direct or indirect) from time to time.

Investors should review the relevant Key Information Document (KID) prior to making an investment decision. These can be obtained free of charge from www.slcapital.com/slpet/index.html or by writing to abrdn Capital Partners LLP, 1 George Street, Edinburgh, Scotland, United Kingdom, EH2 2LL. abrdn Capital Partners LLP is registered in Scotland (SO301408) at 1 George Street, Edinburgh EH2 2LL. abrdn Investment Management Limited acts as Investment Manager for Standard Life Assurance Limited and Standard Life Pension Funds Limited. Standard Life Assurance Limited is registered in Scotland (SC286833) at Standard Life House, 30 Lothian Road, Edinburgh EH1 2DH. abrdn Investment Management Limited is authorised and regulated by the Financial Conduct Authority. Standard Life Assurance Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority.

### For professional investors only

#### Not for public distribution

### Past performance does not predict future returns. The value of investments, and the income from them, can go down as well as up and clients may get back less than the amount invested.

The information contained in this document should not be considered as an offer, solicitation or investment recommendation to deal in the shares of any securities or financial instruments. It is not intended for distribution or use by any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication or use would be prohibited. Nothing herein constitutes investment, legal, tax or other advice and is not to be relied upon in making an investment or other decision. No recommendation is made, positive or otherwise, regarding individual securities mentioned. This is not an invitation to subscribe for shares in the fund and is by way of information only.

The information contained herein including any expressions of opinion or forecast have been obtained from or is based upon sources believed by us to be reliable but is not guaranteed as to the accuracy or completeness.

Any data contained herein which is attributed to a third party ("Third Party Data") is the property of (a) third party supplier(s) (the "Owner") and is licensed for use abrdn\*. Third Party Data may not be copied or distributed. Third Party Data is provided "as is" and is not warranted to be accurate, complete or timely. To the extent permitted by applicable law, none of the Owner, abrdn\* or any other third party (including any third party involved in providing and/or compiling Third Party Data) shall have any liability for Third Party Data or for any use made of Third Party Data. Neither the Owner nor any other third party sponsors, endorses or promotes the fund or product to which Third Party Data relates.

\* abrdn means the relevant member of abrdn group, being abrdn plc together with its subsidiaries, subsidiary undertakings and associated companies (whether direct or indirect) from time to time.

United Kingdom: Issued abrdn Capital Partners LLP, registered in Scotland (No. SO301408), 1 George Street Edinburgh EH2 2LL. Authorised and regulated by the Financial Conduct Authority in the UK

GB-310123-187124-2